vimarsana.com
  1. Home
  2. Live Updates
  3. Immunologic Diseases - Breaking News

Latest Breaking News On - Immunologic diseases - Page 1 : vimarsana.com

Vera Reports Positive Data In Phase 2b ORIGIN Clinical Trial OLE In IgA Nephropathy; Stock Up

Vera Therapeutics, Inc. (VERA), a late clinical-stage biotechnology company focused on serious immunologic diseases, announced Thursday positive 72-week data from the open label extension or OLE period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy or IgAN.

New yorkUnited statesMarshall fordyceMore such health newsVera therapeutics incVera therapeuticsChief executive officerIga nephropathyEra 72 week data2 week dataRigin clinical trialImmunologic diseases

Reticulocyte Hemoglobin Content: Early Marker of Iron-Deficiency Anemia

Is reticulocyte hemoglobin content a better marker of iron deficiency anemia than ferritin and other traditional serum measurements?

United statesClin chim actaRachel zigantiCharity starkesWorld health organizationDepartment of rheumaticWorld healthLaboratory markersReticulocyte hemoglobinPhysician assistant programAugusta universityImmunologic diseasesCleveland clinicMineral nutrition informationAccessed june

Patient Subgroups and Educational Opportunities in Rare Dermatological Disorders

Dermatological experts discuss challenges that are associated with the use of standard and emerging treatments in special patient population.

Identifying rare dermatologic disordersCritical care settingEducational opportunitiesRare dermatologicalRare dermatological disordersImmunologic diseases

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

<p>HONG KONG SAR - <a href="https://www.media-outreach.com/">Media OutReach</a> - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - <b>SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company")</b>, is pleased to announce that Phase III clinical trial of SinoMab s flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.</p>

Hong kongDrug administrationA nationalNational clinical research centerSignificant new drugs development of the twelfthSinomab bioscienceAmerican college of rheumatologyNational medical products administrationSinomab bioscience limited stock codeHong kong basedMab bioscience limitedStock codeAmerican collegeNational reportImmunologic diseasesBiologics license application

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis
livenews.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livenews.co.nz Daily Mail and Mail on Sunday newspapers.

National medical products administrationAmerican college of rheumatologyNational clinical research centerA nationalDrug administrationSinomab bioscience limited stock codeMedia outreachHong kong basedSinomab bioscience limitedStock codeAmerican collegeNational reportImmunologic diseasesBiologics license applicationPhasei first in humanDrug evaluation
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.